Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.7.49 extracted from

  • Arion, D.; Fletcher, R.S.; Borkow, G.; Camarasa, M.J.; Balzarini, J.; Dmitrienko, G.I.; Parniak, M.A.
    Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and 2',5'-bis-o-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)(TSAO) (1996), Mol. Pharmacol., 50, 1057-1064.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
1-[2',5'-bis-O-(t-butyldimethylsilyl)beta-D-ribofuranosyl]-3'-spiro-5''-(4''amino-1'',2''-oxathiole-2'',2''-dioxide)-3-ethylthymine
-
Human immunodeficiency virus 1
9-aminonevirapine
-
Human immunodeficiency virus 1

Organism

Organism UniProt Comment Textmining
Human immunodeficiency virus 1
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
deoxynucleoside triphosphate + DNAn
-
Human immunodeficiency virus 1 diphosphate + DNAn+1
-
?